# CRB-913 Obesity Research: What CANYON-1 Is Actually Measuring Evidence & Research Status Evidence LevelEarly-Stage Human Data (Phase 1) FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) — not for human consumption Last UpdatedSeptember 4, 2026 What This Article Covers CRB-913 obesity research reached a milestone on 4 August 2026, when Corbus Pharmaceuticals announced the last patient's last visit in CANYON-1, its Phase 1b study. Topline data was released on 14 September 2026 and is summarised in the update note above. Primary References [announced the last patient's last visit](https://www.globenewswire.com/news-release/2026/08/04/3338314/0/en/corbus-pharmaceuticals-announces-last-patient-last-visit-in-canyon-1-study-of-crb-913-for-the-treatment-of-obesity.html) [reported](https://ir.corbuspharma.com/news-events/press-releases/detail/458/corbus-pharmaceuticals-reports-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913-for-the-treatment-for-obesity-demonstrating-favorable-safety-profile-and-emerging-evidence-of-weight-loss) Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use. Update — September 18, 2026 CANYON-1 has read out. On 14 September 2026 Corbus Pharmaceuticals [reported topline data](https://ir.corbuspharma.com/news-events/press-releases/detail/478/corbus-pharmaceuticals-announces-positive-topline-data-from-canyon-1-study-of-daily-oral-crb-913-for-the-treatment-of-obesity) from the 16-week, placebo-controlled Phase 1b study in 240 adults with obesity and without diabetes. Trial data showed statistically significant separation from placebo at all three once-daily oral dose levels evaluated (20 mg, 40 mg and 60 mg), with the 60 mg group showing a mean body-weight reduction of approximately 5% at twelve weeks. The sponsor also reported fewer gastrointestinal adverse events than published figures for marketed oral GLP-1 agents — a comparison drawn across separate trials, not head-to-head. This supersedes the sentence below stating that topline data was “expected this month”, and it answers the open question this article was written around. Two cautions the headline figure does not carry. First, approximately 5% at twelve weeks is a smaller magnitude than figures reported for incretin agents in trials of comparable or longer duration, so what makes this mechanism interesting is that it is non-incretin and orally administered, not the size of the effect. Second, a cross-trial safety comparison is not a randomised comparison; nothing reported here establishes that CRB-913 is better tolerated than any specific approved product. Full results are scheduled for a late-breaking presentation at ObesityWeek 2026 (14–17 November), and no peer-reviewed publication exists yet. Corbus has stated it intends to discuss the development plan with FDA and to begin a Phase 2 monotherapy study in the first half of 2027. CRB-913 remains an investigational small molecule held by its sponsor; it is not catalogued by any supplier and is not sold by Portal to Wellness. Compounds we track but do not stock are listed on our [compound watchlist](https://portaltowellness.net/request-compound/) . CRB-913 obesity research reached a milestone on 4 August 2026, when Corbus Pharmaceuticals [announced the last patient’s last visit](https://www.globenewswire.com/news-release/2026/08/04/3338314/0/en/corbus-pharmaceuticals-announces-last-patient-last-visit-in-canyon-1-study-of-crb-913-for-the-treatment-of-obesity.html) in CANYON-1, its Phase 1b study. Topline data was released on 14 September 2026 and is summarised in the update note above. Development stage CRB-913 - Preclinical - Phase 1 - Phase 2 - Phase 3 - Regulatory review - Approved What has been shown in humans? A Phase 1a study reported a mean 2.9% placebo-adjusted body-weight change by Day 14 in a small obese multiple-ascending-dose cohort (n=9 active, n=3 placebo). CANYON-1, a 16-week placebo-controlled Phase 1b in 240 participants, reported topline results on 14 September 2026: statistically significant separation from placebo at 20 mg, 40 mg and 60 mg once daily, with a mean body-weight reduction of approximately 5% at twelve weeks in the 60 mg group. Full data have not been presented or peer-reviewed. Sponsored by Corbus Pharmaceuticals (NASDAQ: CRBP). CRB-913 is a small molecule, not a peptide. A weight signal at 14 days in nine participants does not establish durable efficacy, and Phase 1b readouts frequently differ from Phase 1a expectations. Portal to Wellness does not sell this compound. Accurate as of 18 September 2026. [Corbus IR, 4 Aug 2026](https://ir.corbuspharma.com/news-events/press-releases/detail/474/corbus-pharmaceuticals-announces-last-patient-last-visit-in-canyon-1-study-of-crb-913-for-the-treatment-of-obesity) ## Why a cannabinoid receptor compound is in an obesity pipeline at all CRB-913 is an orally administered inverse agonist at cannabinoid receptor type 1 (CB1). CB1 antagonism is not a new idea in metabolic research — it is a mechanism with a well-documented history and a well-documented failure. Rimonabant, a first-generation CB1 inverse agonist, was approved in Europe in 2006 and withdrawn in 2008. The compound produced weight reduction in trials, but it also crossed the blood–brain barrier readily, and post-marketing surveillance associated it with serious neuropsychiatric events. The mechanism was not abandoned because it failed to work; it was abandoned because of where in the body it worked. That history is the entire premise of the current generation. Corbus describes CRB-913 as **peripherally restricted** — engineered for markedly reduced brain penetration relative to rimonabant while retaining comparable preclinical potency at the receptor. Whether that engineering translates into a different safety picture in humans is precisely the open question, and it is not one that a Phase 1b of this size can settle on its own. ## What the CANYON-1 design tells you CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging study in 240 non-diabetic adults with obesity, run across multiple U.S. sites. Participants were assigned to placebo or to CRB-913 arms titrating from 20 mg/day up to 40 mg/day or 60 mg/day, taken orally once daily. Two features of that design are worth reading carefully. **It is dose-ranging, not confirmatory.** A study structured to compare three exposure levels against placebo is built to identify a tolerable range and observe how response scales with it. It is not powered as a definitive efficacy trial, and a headline percentage from it should not be read alongside Phase 3 numbers from incretin programmes as though the two were comparable measurements. **Sixteen weeks is short for a body-composition question.** The GLP-1 trials that dominate this space report at 68 or 72 weeks. Four months of exposure constrains what can be observed about durability, plateau behaviour, or what happens on discontinuation. ## What Phase 1a established, and what it did not The earlier Phase 1a study included a multiple-ascending-dose cohort in obese participants at 150 mg/day. Corbus [reported](https://ir.corbuspharma.com/news-events/press-releases/detail/458/corbus-pharmaceuticals-reports-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913-for-the-treatment-for-obesity-demonstrating-favorable-safety-profile-and-emerging-evidence-of-weight-loss) that all nine CRB-913-treated participants and none of the three placebo participants showed weight reduction, with a mean placebo-adjusted change of 2.9% by Day 14. Investigators should hold that figure loosely. Nine active participants over fourteen days is a signal-detection result, not an effect-size estimate. The confidence interval around a mean drawn from that sample is wide, and two-week weight change in a controlled setting is heavily influenced by fluid balance rather than tissue composition. The finding justified continuing into Phase 1b. It does not forecast what Phase 1b will report. ## The mechanistic question researchers are actually watching Preclinical work in diet-induced obesity mouse models examined CRB-913 alongside [tirzepatide](https://portaltowellness.net/shop/tirzepatide-60mg/) , [semaglutide](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) , and liraglutide, and reported that combining the CB1 inverse agonist with each incretin produced greater weight reduction than the incretin alone. That is the mechanistically interesting claim: CB1 antagonism operates through a pathway orthogonal to incretin receptor agonism, so the two are not obviously redundant. Findings in mice do not establish effects in humans. What the rodent work does is frame the design question for the field — whether a non-incretin mechanism is best evaluated on its own or as a component in combination, and whether the peripheral-restriction engineering holds up under longer exposure than any human study has yet applied. ## How CRB-913 sits against the compounds researchers already track | Compound | Class | Target | Route | Furthest reported human stage | | --- | --- | --- | --- | --- | | CRB-913 | Small molecule | CB1 (inverse agonist) | Oral | Phase 1b complete, unreported | | Semaglutide | Peptide | GLP-1R | Injectable / oral | Approved | | Tirzepatide | Peptide | GIP + GLP-1R | Injectable | Approved | | Retatrutide | Peptide | GIP + GLP-1R + glucagon R | Injectable | Phase 3 | | Eloralintide | Peptide | Amylin (AMY1R-selective) | Injectable | Phase 2 | | Petrelintide | Peptide | Amylin | Injectable | Phase 3 | The row that does not look like the others is the point. Every other entry is a peptide acting on an incretin or amylin receptor. CRB-913 is a small molecule on a different receptor entirely — which is why a readout from it carries information the incretin trials cannot supply, in either direction. Researchers tracking the amylin side of that table may also want the [petrelintide trial data summary](https://portaltowellness.net/research/petrelintide-amylin-analog-phase-3/) , and those following muscle-preservation mechanisms can compare it against [HM17321 research](https://portaltowellness.net/research/hm17321-muscle-preservation-obesity-research/) . ## Open questions for researchers - Does peripheral restriction hold at the top of the dose range? The neuropsychiatric signal that ended rimonabant was dose- and exposure-related, and 60 mg/day is the highest exposure tested in humans over a sustained period so far. - How does response scale across 20, 40, and 60 mg/day? A flat dose–response and a steep one imply very different development paths. - What did the study measure about composition, as distinct from weight? Sixteen weeks with DXA would say considerably more than sixteen weeks with a scale. - Does the combination hypothesis from the rodent work get tested in humans, and on what timeline? - What is the discontinuation picture? No human data addresses it. ## Where this leaves the compound CRB-913 is not obtainable. It is a sponsor-held small molecule with no supplier catalogue listing and no CAS number in circulation among research-chemical vendors. It is not a peptide, and it is not a candidate for the research market in any near-term sense. Its relevance is informational: it is the most advanced non-incretin mechanism with a human readout imminent, and the September topline will move the field’s estimate of whether CB1 antagonism can be rehabilitated. If you track a compound that Portal to Wellness does not stock and want it considered, it can be [submitted through the compound request page](https://portaltowellness.net/request-compound/) , which also carries the current watchlist. --- *All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.* ### Continue Your Research Related Articles [Body Recomposition with GLP-1 Peptides: What the Research Shows](https://portaltowellness.net/research/body-recomposition-glp1-research/) [Visceral Fat and Metabolic Health: What Researchers Are Studying](https://portaltowellness.net/research/visceral-fat-metabolic-health-research/) Related Products [Compound ES-70 – Endurance & Stamina Series (Research Use Only)](https://portaltowellness.net/shop/compound-es-70-70mg-100-tablets/) BPC-157 500mcg + TB-500 500mcg Oral – 100 Capsules (Research Use Only) Related Research Guide [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/) Related Category [Browse: Incretin & Metabolic](https://portaltowellness.net/incretin-agonists/) Related FAQ [General Research & Ordering FAQ](https://portaltowellness.net/faq/) More Research [Browse the full PTW Research Hub →](https://portaltowellness.net/research/) --- Source: https://portaltowellness.net/research/crb-913-obesity-research-canyon-1/ Research use only. Terms: https://portaltowellness.net/research-use-only/